{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:22:22Z","timestamp":1774430542664,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2018-04577"],"award-info":[{"award-number":["RGPIN-2018-04577"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015370","name":"Northern Ontario Heritage Fund Corporation","doi-asserted-by":"publisher","award":["Not available"],"award-info":[{"award-number":["Not available"]}],"id":[{"id":"10.13039\/100015370","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern Cancer Foundation, Canada","award":["Not available"],"award-info":[{"award-number":["Not available"]}]},{"DOI":"10.13039\/501100000038","name":"Natural Science and Engineering Research Council of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many agents targeting the colchicine binding site in tubulin have been developed as potential anticancer agents. However, none has successfully made it to the clinic, due mainly to dose limiting toxicities and the emergence of multi-drug resistance. Chalcones targeting tubulin have been proposed as a safe and effective alternative. We have shown previously that quinolone chalcones target tubulin and maintain potent anti-proliferative activity vis-\u00e0-vis colchicine, while also having high tolerability and low toxicity in mouse models of cancer and refractivity to multi-drug resistance mechanisms. To identify the most effective anticancer chalcone compound, we synthesized 17 quinolone\u2013chalcone derivatives based on our previously published CTR-17 and CTR-20, and then carried out a structure\u2013activity relationship study. We identified two compounds, CTR-21 [((E)-8-Methoxy-3-(3-(2-methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one)] and CTR-32 [((E)-3-(3-(2-ethoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one)] as potential leads, which contain independent moieties that play a significant role in their enhanced activities. At the nM range, CTR-21 and CTR-32 effectively kill a panel of different cancer cells originated from a variety of different tissues including breast and skin. Both compounds also effectively kill multi-drug resistant cancer cells. Most importantly, CTR-21 and CTR-32 show a high degree of selectivity against cancer cells. In silico, both of them dock near the colchicine-binding site with similar energies. Whereas both CTR-21 and CTR-32 effectively prevents tubulin polymerization, leading to the cell cycle arrest at G2\/M, CTR-21 has more favorable metabolic properties. Perhaps not surprisingly, the combination of CTR-21 and ABT-737, a Bcl-2 inhibitor, showed synergistic effect in killing cancer cells, since we previously found the \u201cparental\u201d CTR-20 also exhibited synergism. Taken together, CTR-21 can potentially be a highly effective and relatively safe anticancer drug.<\/jats:p>","DOI":"10.1038\/s41598-021-01058-z","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T11:04:18Z","timestamp":1635937458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lead optimization of novel quinolone chalcone compounds by a structure\u2013activity relationship (SAR) study to increase efficacy and metabolic stability"],"prefix":"10.1038","volume":"11","author":[{"given":"James","family":"Knockleby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A\u00efcha Dede","family":"Djigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indeewari Kalhari","family":"Lindamulage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrabose","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13010008","author":"EC McLoughlin","year":"2020","unstructured":"McLoughlin, E. C. & O\u2019Boyle, N. M. Colchicine-binding site inhibitors from chemistry to clinic: A review. Pharmaceuticals https:\/\/doi.org\/10.3390\/ph13010008 (2020).","journal-title":"Pharmaceuticals"},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1038\/s41598-019-42816-4","volume":"9","author":"VR Solomon","year":"2019","unstructured":"Solomon, V. R., Pundir, S. & Lee, H. Examination of novel 4-aminoquinoline derivatives designed and synthesized by a hybrid pharmacophore approach to enhance their anticancer activities. Sci. Rep. 9, 6315. https:\/\/doi.org\/10.1038\/s41598-019-42816-4 (2019).","journal-title":"Sci. Rep."},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bioorg.2019.03.038","volume":"87","author":"KP Rakesh","year":"2019","unstructured":"Rakesh, K. P., Kumara, H. K., Manukumar, H. M. & Gowda, D. C. Anticancer and DNA binding studies of potential amino acids based quinazolinone analogs: Synthesis, SAR and molecular docking. Bioorg. Chem. 87, 252\u2013264. https:\/\/doi.org\/10.1016\/j.bioorg.2019.03.038 (2019).","journal-title":"Bioorg. Chem."},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bioorg.2019.02.030","volume":"86","author":"B Moku","year":"2019","unstructured":"Moku, B., Ravindar, L., Rakesh, K. P. & Qin, H. L. The significance of N-methylpicolinamides in the development of anticancer therapeutics: Synthesis and structure\u2013activity relationship (SAR) studies. Bioorg. Chem. 86, 513\u2013537. https:\/\/doi.org\/10.1016\/j.bioorg.2019.02.030 (2019).","journal-title":"Bioorg. Chem."},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejmech.2019.03.063","volume":"173","author":"WY Fang","year":"2019","unstructured":"Fang, W. Y. et al. Synthetic approaches and pharmaceutical applications of chloro-containing molecules for drug discovery: A critical review. Eur. J. Med. Chem. 173, 117\u2013153. https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.063 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"9487","DOI":"10.1039\/C7RA13754K","volume":"8","author":"C Zhao","year":"2018","unstructured":"Zhao, C. et al. Arylnaphthalene lactone analogues: Synthesis and development as excellent biological candidates for future drug discovery. RSC Adv. 8, 9487\u20139502 (2018).","journal-title":"RSC Adv."},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.bmc.2017.11.026","volume":"26","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs. Bioorg. Med. Chem. 26, 340\u2013355. https:\/\/doi.org\/10.1016\/j.bmc.2017.11.026 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ejmech.2018.04.011","volume":"151","author":"L Li","year":"2018","unstructured":"Li, L. et al. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. Eur. J. Med. Chem. 151, 482\u2013494. https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.011 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"10298","DOI":"10.1038\/s41598-017-10972-0","volume":"7","author":"IK Lindamulage","year":"2017","unstructured":"Lindamulage, I. K. et al. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function. Sci. Rep. 7, 10298. https:\/\/doi.org\/10.1038\/s41598-017-10972-0 (2017).","journal-title":"Sci. Rep."},{"key":"1058_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021847118","author":"S Matthew","year":"2021","unstructured":"Matthew, S. et al. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site. Proc. Natl. Acad. Sci. U. S. A. https:\/\/doi.org\/10.1073\/pnas.2021847118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1039\/c9np00053d","volume":"37","author":"AL Risinger","year":"2020","unstructured":"Risinger, A. L. & Du, L. Targeting and extending the eukaryotic druggable genome with natural products: Cytoskeletal targets of natural products. Nat. Prod. Rep. 37, 634\u2013652. https:\/\/doi.org\/10.1039\/c9np00053d (2020).","journal-title":"Nat. Prod. Rep."},{"key":"1058_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030586","author":"A Fong","year":"2019","unstructured":"Fong, A., Durkin, A. & Lee, H. The potential of combining tubulin-targeting anticancer therapeutics and immune therapy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20030586 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1058_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.13126","volume":"83","author":"D Bates","year":"2017","unstructured":"Bates, D. & Eastman, A. Microtubule destabilising agents: Far more than just antimitotic anticancer drugs. Br. J. Clin. Pharmacol. 83, 255\u2013268. https:\/\/doi.org\/10.1111\/bcp.13126 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1016\/j.bmc.2014.02.035","volume":"22","author":"JJ Field","year":"2014","unstructured":"Field, J. J., Kanakkanthara, A. & Miller, J. H. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg. Med. Chem. 22, 5050\u20135059. https:\/\/doi.org\/10.1016\/j.bmc.2014.02.035 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2174\/1568026619666190618130008","volume":"19","author":"Y Duan","year":"2019","unstructured":"Duan, Y., Liu, W., Tian, L., Mao, Y. & Song, C. Targeting tubulin-colchicine site for cancer therapy: Inhibitors, antibody-drug conjugates and degradation agents. Curr. Top. Med. Chem. 19, 1289\u20131304. https:\/\/doi.org\/10.2174\/1568026619666190618130008 (2019).","journal-title":"Curr. Top. Med. Chem."},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/1568009616666160928110818","volume":"17","author":"B Kumar","year":"2017","unstructured":"Kumar, B., Kumar, R., Skvortsova, I. & Kumar, V. Mechanisms of tubulin binding ligands to target cancer cells: Updates on their therapeutic potential and clinical trials. Curr. Cancer Drug Targets 17, 357\u2013375. https:\/\/doi.org\/10.2174\/1568009616666160928110818 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet, C. & Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790\u2013803. https:\/\/doi.org\/10.1038\/nrd3253 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","volume":"29","author":"Y Lu","year":"2012","unstructured":"Lu, Y., Chen, J., Xiao, M., Li, W. & Miller, D. D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res. 29, 2943\u20132971. https:\/\/doi.org\/10.1007\/s11095-012-0828-z (2012).","journal-title":"Pharm. Res."},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drup.2007.06.003","volume":"10","author":"M Schmidt","year":"2007","unstructured":"Schmidt, M. & Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 10, 162\u2013181. https:\/\/doi.org\/10.1016\/j.drup.2007.06.003 (2007).","journal-title":"Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/med.20242","volume":"31","author":"RA Stanton","year":"2011","unstructured":"Stanton, R. A., Gernert, K. M., Nettles, J. H. & Aneja, R. Drugs that target dynamic microtubules: A new molecular perspective. Med. Res. Rev. 31, 443\u2013481. https:\/\/doi.org\/10.1002\/med.20242 (2011).","journal-title":"Med. Res. Rev."},{"key":"1058_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/s0960-894x(98)00162-0","volume":"8","author":"S Ducki","year":"1998","unstructured":"Ducki, S. et al. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 8, 1051\u20131056. https:\/\/doi.org\/10.1016\/s0960-894x(98)00162-0 (1998).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1058_CR23","volume-title":"Vogel's Textbook of Practical Organic Chemistry","author":"AI Vogel","year":"1996","unstructured":"Vogel, A. I., Tatchell, A. R., Furnis, B. S., Hannaford, A. J. & Smith, P. W. G. Vogel\u2019s Textbook of Practical Organic Chemistry (Prentice Hall, 1996)."},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1039\/P19810001531","volume":"1","author":"O Meth-Cohn","year":"1981","unstructured":"Meth-Cohn, O., Narine, B. & Tarnowski, B. A versatile new synthesis of quinolines and related fused pyridines. Part 7. The conversion of acetamidothiophens into thienopyridines. J. Chem. Soc., Perkin Trans. 1, 1531\u20131536. https:\/\/doi.org\/10.1039\/P19810001531 (1981).","journal-title":"J. Chem. Soc., Perkin Trans."},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0223-5234(01)01245-4","volume":"36","author":"JN Dominguez","year":"2001","unstructured":"Dominguez, J. N. et al. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem. 36, 555\u2013560. https:\/\/doi.org\/10.1016\/s0223-5234(01)01245-4 (2001).","journal-title":"Eur. J. Med. Chem."},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1021\/jm00026a010","volume":"38","author":"R Li","year":"1995","unstructured":"Li, R. et al. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem. 38, 5031\u20135037. https:\/\/doi.org\/10.1021\/jm00026a010 (1995).","journal-title":"J. Med. Chem."},{"key":"1058_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejmech.2012.08.039","volume":"57","author":"R Abonia","year":"2012","unstructured":"Abonia, R. et al. Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity. Eur. J. Med. Chem. 57, 29\u201340. https:\/\/doi.org\/10.1016\/j.ejmech.2012.08.039 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"1058_CR28","unstructured":"Lee, H., Trivedi, P., Karthikeyan, C. & Lindamulage, I. K. Quinolone chalcone compounds and uses thereof. Canada patent (2017)."},{"key":"1058_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943\u2013951. https:\/\/doi.org\/10.1038\/sj.cdd.4402081 (2007).","journal-title":"Cell Death Differ."},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol. Rev."},{"key":"1058_CR31","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1021\/bi9728553","volume":"37","author":"JM Andreu","year":"1998","unstructured":"Andreu, J. M., Perez-Ramirez, B., Gorbunoff, M. J., Ayala, D. & Timasheff, S. N. Role of the colchicine ring A and its methoxy groups in the binding to tubulin and microtubule inhibition. Biochemistry 37, 8356\u20138368. https:\/\/doi.org\/10.1021\/bi9728553 (1998).","journal-title":"Biochemistry"},{"key":"1058_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25051180","author":"D Czerwonka","year":"2020","unstructured":"Czerwonka, D. et al. Synthesis and antiproliferative screening of novel analogs of regioselectively demethylated colchicine and thiocolchicine. Molecules https:\/\/doi.org\/10.3390\/molecules25051180 (2020).","journal-title":"Molecules"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112\u20131116. https:\/\/doi.org\/10.1038\/nprot.2006.179 (2006).","journal-title":"Nat. Protoc."},{"key":"1058_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1385\/1-59259-869-2:039","volume":"110","author":"W Voigt","year":"2005","unstructured":"Voigt, W. Sulforhodamine B assay and chemosensitivity. Methods Mol. Med. 110, 39\u201348. https:\/\/doi.org\/10.1385\/1-59259-869-2:039 (2005).","journal-title":"Methods Mol. Med."},{"key":"1058_CR35","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786. https:\/\/doi.org\/10.1021\/ci200227u (2011).","journal-title":"J. Chem. Inf. Model."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01058-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01058-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01058-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:49:28Z","timestamp":1670086168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01058-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01058-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21576"}}